PALVELLA THERAPEUTICS, INC.(PVLA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

PALVELLA THERAPEUTICS, INC. (PVLA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PVLA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $46.3m in revenue and is scored on the micro-cap board instead. Top institutional holders of PVLA by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT, JENNISON ASSOCIATES, BlackRock, based on the most recent SEC filings. PVLA trades on the Nasdaq exchange and files with the SEC under CIK 1583648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PVLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PALVELLA THERAPEUTICS, INC. directly from SEC EDGAR.

Net Income

$-21.9M

PVLA key financials by period

PALVELLA THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202310-K$42.8M$18.7M-27.7%
FY 202210-K$25.9M$-33.3M-167.8%
FY 202110-K$31.4M$-45.7M-165.0%
FY 202010-K$29.3M$-37.2M-115.7%
FY 201910-K$46.3M$-25.5M-58.7%
FY 201810-K$29.1M$-26.8M-105.9%

Institutions holding PVLA

Institutional investors reporting a position in PALVELLA THERAPEUTICS, INC. on SEC Form 13F.
InstitutionSharesValueReported
SUVRETTA CAPITAL MANAGEMENT1,135,406$173.5M2026-06-30
JENNISON ASSOCIATES960,619$146.8M2026-06-30
BlackRock918,357$140.3M2026-06-30
Frazier Life Sciences Management, L.P.882,400$134.8M2026-06-30
First Light Asset Management771,901$118.0M2026-06-30
BVF672,789$102.8M2026-06-30
STATE STREET653,172$99.8M2026-06-30
PRICE T ROWE ASSOCIATES638,868$97.6M2026-06-30
VANGUARD CAPITAL MANAGEMENT513,794$78.5M2026-06-30
FRONTIER CAPITAL MANAGEMENT478,833$73.2M2026-06-30
SEC EDGAR: CIK 1583648 →
PVLA

PALVELLA THERAPEUTICS, INC.

PVLA
NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $46.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-21.87M

EPS (Diluted)

Q2 2026
EDGAR

$-1.52

ROIC

Q2 2026
EDGAR

-39.5%

Top Institutional Holders

as of Q2 2026
$2.22B total
SUVRETTA CAPITAL MANAGEMENT, LLC
$173.51M-1.6%
JENNISON ASSOCIATES LLC
$146.80M+50.0%
BlackRock, Inc.
$140.34M+33.7%
Frazier Life Sciences Management, L.P.
$134.85M0.0%
First Light Asset Management, LLC
$117.96M-21.3%
BVF INC/IL
$102.82M-30.0%
STATE STREET CORP
$99.82M+42.3%
PRICE T ROWE ASSOCIATES INC /MD/
$97.63M+58.7%
VANGUARD CAPITAL MANAGEMENT LLC
$78.52M+7.6%
FRONTIER CAPITAL MANAGEMENT CO LLC
$73.18M+28.0%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…